Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

U.S. President Donald Trump called Amazon Executive Chairman Jeff Bezos on Tuesday morning to complain about a report the ...

Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

A German pharmaceutical company is acquiring a drug developer with operations in Research Triangle Park.

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Merck KGaA plans to acquire SpringWorks Therapeutics, a Connecticut-based specialist in biopharmaceuticals for severe rare diseases and cancer ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for ...

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...